We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) was a big mover last session, as the company saw its shares jump a little above 16% on the day. The upside was driven by the news that its competing drug candidate, patisiran, is scheduled to announce its phase 3 results soon. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 29% in the past one-month time frame.
The company has seen a mixed track record of two positive and five negative estimate revisions in the past 30 days, while the Zacks Consensus Estimate moved lower over the same timeframe. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Alnylam Pharmaceuticals currently has a Zacks Rank #3 (Hold).
Is ALNY going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) was a big mover last session, as the company saw its shares jump a little above 16% on the day. The upside was driven by the news that its competing drug candidate, patisiran, is scheduled to announce its phase 3 results soon. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 29% in the past one-month time frame.
The company has seen a mixed track record of two positive and five negative estimate revisions in the past 30 days, while the Zacks Consensus Estimate moved lower over the same timeframe. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Alnylam Pharmaceuticals currently has a Zacks Rank #3 (Hold).
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. Price | Alnylam Pharmaceuticals, Inc. Quote
A top-ranked stock in the Medical-Biomedical and Genetics industry is Aeglea BioTherapeutics sporting a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is ALNY going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.See these buy recommendations now >>